According to DataM Intelligence AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics ...

A promising new targeted cancer therapy is now available to certain patients with advanced pancreatic cancer – from the comfort of their home. The treatment is available through a first-of-its-kind, ...

As of Monday, November 10, Cogent Biosciences, Inc.’s COGT share price has surged by 136.17%, which has investors questioning if this is right time to sell.

Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.

Childhood cancer is still the most common cause of deaths in the ages 1–14 years, although today the survival rate is over 85%. Leukaemia is the most common cancer in childhood (30% of paediatric ...

PredicineCARE is a urine-based NGS assay under FDA review for bladder cancer companion diagnostics, detecting genetic alterations in cancer-related genes. The test uses a capture-based method to ...

Tyra Biosciences Inc. recently presented the design and preclinical characterization of TYRA-200, an oral small-molecule FGFR1/2/3 tyrosine kinase inhibitor (TKI) that shows high potency against all ...

Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers-including intrahepatic cholangiocarcinoma, endometrial, breast, gastric, and bladder cancers. However, the ...

Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma Recurrent nonkinase domain FGFR VUS variants were collected from the Catalog of Somatic Mutations in Cancer and their ...